These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 3337101

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis.
    Salusky IB, Coburn JW, Foley J, Nelson P, Fine RN.
    J Pediatr; 1986 May; 108(5 Pt 1):767-70. PubMed ID: 3701525
    [Abstract] [Full Text] [Related]

  • 24. Aluminum toxicity in relation to kidney disorders.
    King SW, Savory J, Wills MR.
    Ann Clin Lab Sci; 1981 May; 11(4):337-42. PubMed ID: 7023347
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder.
    Malberti F, Surian M, Poggio F, Minoia C, Salvadeo A.
    Am J Kidney Dis; 1988 Dec; 12(6):487-91. PubMed ID: 3143260
    [Abstract] [Full Text] [Related]

  • 27. Bone disease in renal failure. Clinical and histomorphometric studies.
    Nilsson P.
    Scand J Urol Nephrol Suppl; 1984 Dec; 84():1-68. PubMed ID: 6393322
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Calcium carbonate and magnesium hydroxide in the prevention of renal osteodystrophy or the demise of aluminum toxicity in uremia. Analysis of 5 years experience.
    Morinière P, Fournier A, Westeel PF, Idrissi A, Renaud H, Hocine C, Belbrik S, Marie A, Leflon P, Sebert JL.
    Contrib Nephrol; 1988 Dec; 64():58-73. PubMed ID: 3053039
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Towards tailored dialysis fluids in CAPD--the role of reduced calcium and magnesium in dialysis fluids.
    Hutchison AJ, Gokal R.
    Perit Dial Int; 1992 Dec; 12(2):199-203. PubMed ID: 1586680
    [No Abstract] [Full Text] [Related]

  • 34. Renal osteodystrophy in children undergoing continuous ambulatory peritoneal dialysis.
    Hewitt IK, Stefanidis C, Reilly BJ, Kooh SW, Balfe JW.
    J Pediatr; 1983 Nov; 103(5):729-34. PubMed ID: 6631599
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Aluminum and renal osteodystrophy in chronic uremia.
    Berland Y, Grandvuillemin M, Charhon S, Olmer M.
    Kidney Int Suppl; 1985 Dec; 17():S183-7. PubMed ID: 3867793
    [No Abstract] [Full Text] [Related]

  • 37. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
    Jenkins DA, Gouldesbrough D, Smith GD, Cowie JF, Winney RJ.
    Nephrol Dial Transplant; 1989 Dec; 4(1):51-6. PubMed ID: 2494599
    [Abstract] [Full Text] [Related]

  • 38. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group.
    Weinreich T, Passlick-Deetjen J, Ritz E.
    Am J Kidney Dis; 1995 Mar; 25(3):452-60. PubMed ID: 7872324
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Aluminum and renal osteodystrophy.
    Sherrard DJ.
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):5-11. PubMed ID: 3299591
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.